Pda Technical Report 82 -

For products in development, TR 82 provides guidance to formulation scientists:

: Evaluating a switch from traditional LAL to biological systems or recombinant Factor C (rFC) assays where appropriate. Regulatory and Clinical Impact

Published in March 2019, PDA Technical Report No. 82 (TR 82) provides a comprehensive framework for understanding and managing Low Endotoxin Recovery (LER) in biopharmaceutical products. The report details hold-time study protocols, outlines mitigation strategies, and features 12 industry case studies to address endotoxin masking, with a revision currently underway to incorporate new scientific advancements. For more details, visit PDA Bookstore Parenteral Drug Association Technical Report No. 82: Low Endotoxin Recovery | PDA pda technical report 82

Disclaimer: This article is for informational purposes and does not replace the full PDA Technical Report 82 or official regulatory guidance. Always consult with your quality assurance and regulatory teams.

LER does not occur in all products. It is driven by specific formulation excipients (e.g., polysorbates, EDTA, histidine, sugars) and container materials. TR 82 provides a systematic approach to determine if your product is susceptible. For products in development, TR 82 provides guidance

The core recommendation of TR 82 is to perform a systematic LER study. This involves:

Polysorbate 80 and 20, common in biologics to prevent aggregation, act as detergents. Endotoxin is a lipopolysaccharide (LPS) anchored in a membrane. TR 82 describes how surfactants can disaggregate LPS from large vesicles into smaller micellar structures. While still pyrogenic, these smaller units bind poorly to the LAL enzyme cascade, leading to artificially low recovery. Always consult with your quality assurance and regulatory

should not sit on a shelf. It represents a fundamental shift in endotoxin control: from a simple "pass/fail" test to a holistic understanding of product-method interaction. The key takeaway from TR 82 is not the specific protocols, but the principle: Absence of evidence is not evidence of absence.

TR 82 explores why masking occurs, highlighting how surfactants coat individual endotoxin monomers once they are dissociated by chelators. It also addresses , where cationic proteins bind to negatively charged endotoxins. 3. Mitigation and Demasking Strategies

If your product contains polysorbate, EDTA, or lives in a prefilled syringe, you must assume LER is possible until you prove otherwise. By implementing the characterization studies, dilution strategies, and orthogonal methods outlined in TR 82, you protect your patients from the hidden risk of masked endotoxin.